Videos

Howard L. Kaufman, MD, a surgical oncologist at Rutgers Cancer Institute of New Jersey, discusses a study which showed further durable responses to avelumab (Bavencio) in patients with merkel cell carcinoma who progressed after chemotherapy.

Long-Term Strategies in Advanced HCC

Later Line Therapeutic Decisions in Metastatic HCC

Later Line Therapeutic Decisions in Metastatic HCC

Jessica Islam, MPH, a PhD student at the University of North Carolina at Chapel Hill Gillings School of Global Public Health, discusses research that projected cancer incidence in the HIV-positive population in the United States through 2030.

Hideho Okada, MD, PhD, director, Brain Tumor Immunotherapy Center, professor of Neurological Surgery, University of California, San Francisco, discusses a study exploring vaccination in low-grade glioma aiming at prevention of high-grade transformation.

Julie R. Brahmer, MD, associate professor of Oncology, Bloomberg Kimmel Institute for Cancer Immunotherapy at Johns Hopkins, discusses why CheckMate-026 was not successful in showing an improvement in progression-free survival (PFS) for patients with advanced non-small cell lung cancer.

Sarah B. Goldberg, MD, MPH, assistant professor of Medicine, Yale Cancer Center, discusses treating patients with non-small cell lung cancer (NSCLC) who do not have an actionable oncogenic driver.

Ruth O’Regan, MD, discusses results of BELLE-3, a phase III study of buparlisib (BKM120) plus fulvestrant (Faslodex) in postmenopausal women with hormone receptor (HR)-positive, HER2-negative breast cancer.

Treatment of Malignant Melanoma